Skip to main content
Premium Trial:

Request an Annual Quote

Almac, AstraZeneca Strike CDx Development Pact

NEW YORK — Almac Diagnostic Services said on Thursday that it signed a master collaboration agreement to develop and commercialize multiple companion diagnostics with UK pharmaceutical firm AstraZeneca.

Under the terms of the deal, Almac will develop and validate companion diagnostic assays for use in selecting patients for AstraZeneca's clinical studies in a range of therapeutic areas including kidney disease, nonalcoholic steatohepatitis, and respiratory disease.

Almac said it will be responsible for obtaining regulatory approval for the assays in specific markets in parallel with AstraZeneca's therapeutics. Financial and other terms were not disclosed.

In early 2021, UK-based Almac partnered with Personal Genome Diagnostics to provide tumor profiling assays to pharmaceutical customers. Almac Diagnostic Services is part of the Almac Group.